Exciting Developments from Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), based in San Carlos, California, is making strides in the realm of cancer treatment through its innovative approaches to tumor infiltrating lymphocyte (TIL) therapies. The company recently announced its participation in notable scientific congresses where it aims to unveil pivotal data regarding its TIL therapies. This is an essential opportunity for the company to showcase its advancements and innovative research in the fight against cancer.
Upcoming Presentations at Scientific Congresses
Iovance will present pre-clinical data on IOV-5001, a groundbreaking genetically engineered TIL cell therapy that incorporates an inducible interleukin-12 (IL-12). This is scheduled for the 2025 AACR Annual Meeting taking place later this month. In addition to this, the company will share five-year outcome data from the C-144-01 study focusing on lifileucel monotherapy for patients battling advanced melanoma. Furthermore, Iovance will discuss the design of a study around lifileucel’s application in frontline advanced non-small cell lung cancer at the 2025 ASCO Annual Meeting.
AACR Meeting Details
The 2025 AACR Annual Meeting will occur from April 25 to April 30 in Chicago. Iovance’s poster presentation will focus on the enhanced antitumor efficacy of IOV-5001, highlighting the improved cellular state of TILs. This presentation is part of a session titled "Immune Fitness and Metabolic Regulation of Cancer Immunity," which is set for April 29, 2025.
ASCO Meeting Insights
Later, at the ASCO Annual Meeting, scheduled for May 30 to June 3, Iovance will deliver a rapid oral presentation on the impressive five-year outcomes of the C-144-01 study. Additionally, the company will feature a trial-in-progress poster illustrating the Phase 2 study that explores the implications of combining lifileucel with pembrolizumab in advanced non-small cell lung cancer. This session focuses on lung cancer and will commence on May 31.
Panel Discussion and Engagement
Iovance has planned a significant panel discussion on the evening of May 31, featuring key opinion leaders in the field of melanoma. This event promises to offer insights into the future of melanoma treatment and the potential impact of Iovance’s therapies. The panel will be accessible via a live and archived webcast, enhancing community engagement and fostering dialogue around these critical advancements in cancer therapy.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is devoted to cementing its position as a leader in the development of TIL therapies. It employs a transformative approach that capitalizes on the human immune system’s capabilities to identify and eradicate diverse cancer cells. The Iovance TIL platform has shown promising clinical data across various solid tumors.
The company has achieved notable recognition with Amtagvi, which is the first FDA-approved T cell therapy for a solid tumor indication. Continuous innovation is at the heart of Iovance's mission, focusing on the development of gene-edited cell therapies that may enhance longevity and quality of life for cancer patients.
Contact Information
If you would like to learn more about Iovance Biotherapeutics and its revolutionary therapies, feel free to reach out to their team via the following contacts:
Investor Inquiries
Email: IR@iovance.com
Phone: 650-260-7120 ext. 150
Media Inquiries
Email: PR@iovance.com
Phone: 650-260-7120 ext. 150
Frequently Asked Questions
What is Iovance Biotherapeutics focused on?
Iovance Biotherapeutics is dedicated to developing innovative polyclonal TIL therapies aimed at treating cancer patients.
What data will Iovance present at upcoming congresses?
The company will showcase pre-clinical data on IOV-5001 and five-year outcomes from the C-144-01 study for lifileucel.
When will the AACR and ASCO meetings take place?
The AACR Annual Meeting is scheduled for April 25-30, and the ASCO Annual Meeting will run from May 30 to June 3.
What events will Iovance host during these meetings?
Iovance will host a panel discussion on May 31 that includes key opinion leaders discussing melanoma research.
How can I get in touch with Iovance for more information?
You can contact Iovance via email at IR@iovance.com for investor inquiries or PR@iovance.com for media inquiries.
